
Global R&D Pipeline
My Favorite
Hot Targets:
CCR8
Back
Total number of drugs
68
Phase II and later clinical stages
5.9%
Involving companies
73
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GNUV-202 | GNUV-202 | Monoclonal antibody | Neoplasms | C-C motif chemokine receptor 8 inhibitors | Genuv, Inc. | Genuv, Inc. | Discovery | GNUV-202 | detail > | ||||||||||||
| WO2024120418 | WO2024120418 | Monoclonal antibody | Neoplasms | Guangdong Fapon Biopharma Inc | Guangdong Fapon Biopharma Inc | Discovery | WO2024120418 | detail > | |||||||||||||
| WO2024115549 | WO2024115549 | Small molecule drug | Neoplasms Infectious Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Other Diseases | C-C motif chemokine receptor 8 modulators | Idorsia Pharmaceuticals Ltd. | Idorsia Pharmaceuticals Ltd. | Discovery | WO2024115549 | detail > | ||||||||||||
| WO2024086684 | WO2024086684 | Monoclonal antibody | Neoplasms | iBio, Inc. | iBio, Inc. | Discovery | WO2024086684 | detail > | |||||||||||||
| WO2024077239 | WO2024077239 | Monoclonal antibody | Neoplasms Digestive System Disorders | Genentech, Inc. | Genentech, Inc. | Discovery | WO2024077239 | detail > | |||||||||||||
| WO2024059909 | WO2024059909 | Antibody | Neoplasms | Monash University | Monash University | Discovery | WO2024059909 | detail > | |||||||||||||
| WO2023230473 | WO2023230473 | Antibody | Neoplasms Other Diseases | Bristol Myers Squibb Co. | Bristol Myers Squibb Co. | Discovery | WO2023230473 | detail > | |||||||||||||
| WO2023208182 | WO2023208182 | Monoclonal antibody | Neoplasms Infectious Diseases Other Diseases | Shanghai Hengrui Pharmaceutical Co., Ltd.Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Discovery | WO2023208182 | detail > | |||||||||||||
| WO2023206350 | WO2023206350 | Antibody | Neoplasms Respiratory Diseases Other Diseases | Discovery | WO2023206350 | detail > | |||||||||||||||
| HFB-101110 | HFB-101110 | Monoclonal antibody | Neoplasms | C-C motif chemokine receptor 8 inhibitors | Hifibio SAS | Hifibio SAS | Preclinical | HFB-101110 | detail > |
Total 68 data
1
2
3
4
5
6
7


